Quick Answer
Silexion Therapeutics Corp reported Net Income of -$11.91 million for fiscal year 2025.
Silexion Therapeutics Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$11.91M +27.9% |
-$16.52M -223.4% |
-$5.11M | — |
| Diluted EPS | $8.96 -97.7% |
$394.94 +792.9% |
$44.23 | — |
| Total Assets | $7.21M +152.0% |
$2.86M -45.5% |
$5.26M | — |
| Cash and Equivalents | $5.99M +404.7% |
$1.19M -74.2% |
$4.59M | — |
| Stockholders Equity | $2.60M +165.3% |
-$3.99M +74.2% |
-$15.48M -304.5% |
$7.57M |
| R&D Expense | $7.14M +22.8% |
$5.82M +56.8% |
$3.71M | — |
| Operating Income | -$11.63M +7.5% |
-$12.57M -168.6% |
-$4.68M | — |
| Shares Outstanding | 3.13B +2436.0% |
123.29M +26.9% |
97.12M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.26M | +72.5% | -30.3% |
| Diluted EPS | September 30, 2025 | $2.88 | -98.9% | -33.3% |
| Total Assets | September 30, 2025 | $11.61M | +276.2% | +100.3% |
| Cash and Equivalents | September 30, 2025 | $9.24M | +368.5% | +166.7% |
| Stockholders Equity | September 30, 2025 | $6.98M | +252.4% | +5714.2% |
| R&D Expense | September 30, 2025 | $2.16M | -32.9% | +111.9% |
| Operating Income | September 30, 2025 | -$3.29M | +59.0% | -44.1% |
| Shares Outstanding | September 30, 2025 | 3.13M | -72.0% | +439.5% |
- Silexion Therapeutics Corp reported Net Income of -$11.91 million for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +27.9% in Net Income compared to the prior fiscal year.
- Silexion Therapeutics Corp reported Diluted EPS of $8.96 per share for fiscal year 2025.
- Silexion Therapeutics Corp showed a decrease of -97.7% in Diluted EPS compared to the prior fiscal year.
- Silexion Therapeutics Corp reported Total Assets of $7.21 million for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +152.0% in Total Assets compared to the prior fiscal year.
- Silexion Therapeutics Corp reported Cash and Equivalents of $5.99 million for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +404.7% in Cash and Equivalents compared to the prior fiscal year.
- Silexion Therapeutics Corp reported Stockholders Equity of $2.60 million for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +165.3% in Stockholders Equity compared to the prior fiscal year.
- Silexion Therapeutics Corp reported R&D Expense of $7.14 million for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +22.8% in R&D Expense compared to the prior fiscal year.
- Silexion Therapeutics Corp reported Operating Income of -$11.63 million for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +7.5% in Operating Income compared to the prior fiscal year.
- Silexion Therapeutics Corp reported Shares Outstanding of 3.13 billion shares for fiscal year 2025.
- Silexion Therapeutics Corp showed an increase of +2436.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: